Why Emergent Biosolutions Inc’s (EBS) Stock Is Down 4.43% (2024)

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Emergent Biosolutions Inc before investing.

In this article, we go over a few key elements for understanding Emergent Biosolutions Inc’s stock price such as:

Before we jump into Emergent Biosolutions Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

Want to learn more about Emergent Biosolutions Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Emergent Biosolutions Inc.

As of June 13, 2024, 4:00 PM, CST, Emergent Biosolutions Inc’s stock price was $6.04.

Emergent Biosolutions Inc is down 4.43% from its previous closing price of $6.32.

During the last market session, Emergent Biosolutions Inc’s stock traded between $6.29 and $6.94. Currently, there are 52.20 million shares of Emergent Biosolutions Inc stock available for purchase.

Unfortunately, Emergent Biosolutions Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Emergent Biosolutions Inc’s (EBS) price is currently up 5.96% so far this month.

During the month of June, Emergent Biosolutions Inc’s stock price has reached a high of $7.18 and a low of $5.52.

Over the last year, Emergent Biosolutions Inc has hit prices as high as $9.96 and as low as $1.42. Year to date, Emergent Biosolutions Inc’s stock is down 48.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 12, 2024, there was 1 analyst who downgraded Emergent Biosolutions Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Emergent Biosolutions Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Emergent Biosolutions Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Emergent Biosolutions Inc’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Emergent Biosolutions Inc (EBS) by visiting AAII Stock Evaluator.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 12, 2024, Emergent Biosolutions Inc has a weighted four-quarter relative price strength of 42.57%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Emergent Biosolutions Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

As of June 13, 2024, Emergent Biosolutions Inc’s stock price is $6.04, which is down 4.43% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Emergent Biosolutions Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.